CD4 and neoplasm: CD4+ T cells engineered to express MHC-I-restricted TCRs can directly target tumour cells instead of relying on MHC-II expression, typically only constitutively expressed on antigen-presenting cells (APCs) or induced on endothelial cells following inflammatory stress.